MedTrace Logo

A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)

NCT03924154 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2020-03-09

No results posted yet for this study

Summary

This is an exploratory Phase 2a, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of RVT-1201 in patients with pulmonary arterial hypertension (PAH).

Conditions

Interventions

DRUG

RVT-1201

RVT-1201 600 mg immediate-release tablet

DRUG

Placebo

Inactive pill manufactured to mimic RVT-1201 600 mg immediate-release tablet

Sponsors & Collaborators

  • Altavant Sciences, Inc.

    collaborator UNKNOWN

  • PPD Development, LP

    collaborator INDUSTRY

  • Altavant Sciences GmbH

    lead INDUSTRY

Principal Investigators

  • Ed Parsley, DO · Altavant Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2020-02-24
Completion
2020-02-24
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03924154 on ClinicalTrials.gov